Trials / Withdrawn
WithdrawnNCT00485966
Study Evaluating Effects of CX-3543 in Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia
A Phase 2, Multi-Center, Open Label Study Evaluating Clinical Efficacy, Safety, and Pharmacodynamic Effects of Quarfloxacin (CX-3543) in Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL)
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 25 (estimated)
- Sponsor
- Cylene Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase 2, open-label, multicenter, efficacy, safety, and pharmacodynamic study of CX-3543 in patients with relapsed or refractory B-cell chronic lymphocytic leukemia (CLL).
Detailed description
The purpose of this trial is to evaluate the response rate, safety, pharmacodynamic effects, and duration of response of CX-3543 in patients with relapsed or refractory B-cell CLL.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CX-3543 | 360 mg/m2 daily x 5 q 21 days |
Timeline
- Start date
- 2007-06-01
- Completion
- 2008-06-01
- First posted
- 2007-06-13
- Last updated
- 2008-11-05
Locations
7 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00485966. Inclusion in this directory is not an endorsement.